Newsletter Subject

[Tickers Inside] 7 Solid Gainers Over the Last 5 Sessions

From

marketsectordaily.com

Email Address

editor@marketsectordaily.com

Sent On

Fri, Sep 30, 2022 06:31 PM

Email Preheader Text

Stocks with 5 days of consecutive price advances. --------------------------------------------------

Stocks with 5 days of consecutive price advances. --------------------------------------------------------------- [Lithium Triangle a "Treasure Trove"for the Popular Energy Metal]() [Put this company on your radar now.](=) --------------------------------------------------------------- September 30, 2022 From the desk of the Editor (5 Day Gainers Report) Dear Reader, We just identified 7 Five Day Gainers of all US Exchanges. If you are interested in any of these companies, we encourage you to do your own research and due diligence. Keep reading to see what we just uncovered... --------------------------------------------------------------- [Biden Warns America on China: "They're Going to Eat Our Lunch"]( new cold war over "white gold" is unfolding. This affects every cell phone, laptop... even tools in your home. But one small company is poised to break the Chinese stranglehold and reward savvy investors. [Find out what you need to know in this report.]( --------------------------------------------------------------- [AKOUOS, AKUS]() Recent Analyst Action: Sami Corwin, analyst at William Blair, reiterates coverage on [AKOUOS (AKUS)](=)in the Healthcare sector with a Buy rating and a price target of $12.00 (1 day ago). - Recent Price: $6.94 - Average Analyst Price Target: $24.00 (245.82%) - Market Cap: $198.89M [TipRanks.com]() also reports that [AKOUOS](currently has 4 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $24.00. The target pricing ranges from a high forecast of $35.00 down to a low forecast of $12.00. [AKOUOS (AKUS)](’s last closing price was $6.94 which would put the average price target at $24.00. Here are 3rd party ratings for [AKUS](): - TipRanks.com: Strong Buy - TradingView.com: Strong Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: buy - Zacks.com: Buy, Top 33% (84 out of 251) [Click here for chart >>](=) -------------------------------------------------------------------------- --------------------------------------------------------------- [These 2 Dividend Stocks Pay Every Week]() you still looking for consistent income in this near-zero interest rate environment? There is a better way. I just revealed the Holy Grail of dividend stocks - a safe, reliable and consistent stock that [pays dividends EVERY single week](- 52 times a year. It's simple: Buy the stock this Monday and you'll get your first dividend payout in your bank account this Thursday....and then every Thursday after for as long as you own the stock! [Tap here to reveal the name of this stock for FREE.]() --------------------------------------------------------------- [Immuneering, IMRX](=) Recent Analyst Action: Geulah Livshits, analyst at Chardan Capital, reiterates coverage on [Immuneering (IMRX)]()in the Services sector with a Buy rating and a price target of $18.00 (1 month ago). - Recent Price: $15.47 - Average Analyst Price Target: $23.67 (53.01%) - Market Cap: $328.58M [TipRanks.com]( also reports that [Immuneering](=)currently has 3 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $23.67. The target pricing ranges from a high forecast of $41.00 down to a low forecast of $12.00. [Immuneering (IMRX)]()’s last closing price was $15.47 which would put the average price target at $23.67. Here are 3rd party ratings for [IMRX](=): - TipRanks.com: Moderate Buy - TradingView.com: Strong Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong buy - Zacks.com: Buy, Top 33% (84 out of 251) [Click here for chart >>]() -------------------------------------------------------------------------- [Neuronetics, STIM]( Recent Analyst Action: David Turkaly, analyst at JMP Securities, reiterates coverage on [Neuronetics (STIM)](in the Healthcare sector with a Buy rating and a price target of $12.00 (1 month ago). - Recent Price: $3.25 - Average Analyst Price Target: $10.50 (223.08%) - Market Cap: $78.37M [TipRanks.com]( also reports that [Neuronetics](currently has 3 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $10.50. The target pricing ranges from a high forecast of $12.00 down to a low forecast of $9.00. [Neuronetics (STIM)](’s last closing price was $3.25 which would put the average price target at $10.50. Here are 3rd party ratings for [STIM](: - TipRanks.com: Moderate Buy - TradingView.com: Neutral - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Weak sell - Zacks.com: Hold, Bottom 33% (169 out of 251) [Click here for chart >>]() -------------------------------------------------------------------------- --------------------------------------------------------------- Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast: ["Prepare for Five Years of Famine"]() [Click here]() for the name of the one ticker you need to protect yourself. --------------------------------------------------------------- [Akero Therapeutics, AKRO]( Recent Analyst Action: Matthew Harrison, analyst at Morgan Stanley, reiterates coverage on [Akero Therapeutics (AKRO)](=)in the Healthcare sector with a Hold rating and a price target of $30.00 (2 weeks ago). - Recent Price: $34.32 - Average Analyst Price Target: $43.00 (25.29%) - Market Cap: $1.34B [TipRanks.com]() also reports that [Akero Therapeutics](currently has 4 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $43.00. The target pricing ranges from a high forecast of $62.00 down to a low forecast of $30.00. [Akero Therapeutics (AKRO)](=)’s last closing price was $34.32 which would put the average price target at $43.00. Here are 3rd party ratings for [AKRO](: - TipRanks.com: Strong Buy - TradingView.com: Strong Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong buy - Zacks.com: Hold, Top 33% (84 out of 251) [Click here for chart >>](=) -------------------------------------------------------------------------- [Innovid, CTV]( Recent Analyst Action: Brian Nowak, analyst at Morgan Stanley, reiterates coverage on [Innovid (CTV)](in the Technology sector with a Sell rating and a price target of $2.7 (2 weeks ago). - Recent Price: $2.675 - Average Analyst Price Target: $4.90 (83.18%) - Market Cap: $316.54M [TipRanks.com]( also reports that [Innovid]()currently has 3 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $4.90. The target pricing ranges from a high forecast of $6.00 down to a low forecast of $2.70. [Innovid (CTV)](’s last closing price was $2.675 which would put the average price target at $4.90. Here are 3rd party ratings for [CTV](): - TipRanks.com: Moderate Buy - TradingView.com: Sell - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: Hold, Top 37% (93 out of 251) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- [Copper Exploration Heating Up]() =Canada is already known as a miner's paradise. But British Columbia (BC) is quietly becoming the new copper hotspot. That's because copper is critical to the world's shift to renewable energy. Biden earmarked $226 billion in new infrastructure projects all requiring copper. [Discover the Opportunities in the New Copper Hotspot.]() --------------------------------------------------------------- [Local Bounti Corporation, LOCL]( Recent Analyst Action: Colin Rusch, analyst at Oppenheimer, reiterates coverage on [Local Bounti Corporation (LOCL)](=)in the Financial sector with a Buy rating (2 days ago). - Recent Price: $2.9 - Average Analyst Price Target: $9.50 (227.59%) - Market Cap: $269.43M [TipRanks.com]() also reports that [Local Bounti Corporation](=)currently has 5 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $9.50. The target pricing ranges from a high forecast of $15.00 down to a low forecast of $4.00. [Local Bounti Corporation (LOCL)](’s last closing price was $2.9 which would put the average price target at $9.50. Here are 3rd party ratings for [LOCL](: - TipRanks.com: Strong Buy - TradingView.com: Neutral - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: Hold, Bottom 8% (232 out of 251) [Click here for chart >>]( -------------------------------------------------------------------------- [Tricida, TCDA]() Recent Analyst Action: Madhu Kumar, analyst at Goldman Sachs, reiterates coverage on [Tricida (TCDA)](=)in the Healthcare sector with a Buy rating and a price target of $20.00 (1 month ago). - Recent Price: $10.9 - Average Analyst Price Target: $19.00 (74.31%) - Market Cap: $551.12M [TipRanks.com]() also reports that [Tricida](currently has 2 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $19.00. The target pricing ranges from a high forecast of $20.00 down to a low forecast of $18.00. [Tricida (TCDA)](’s last closing price was $10.9 which would put the average price target at $19.00. Here are 3rd party ratings for [TCDA](): - TipRanks.com: Moderate Buy - TradingView.com: Strong Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: buy - Zacks.com: Hold, Top 33% (84 out of 251) [Click here for chart >>](=) -------------------------------------------------------------------------- --------------------------------------------------------------- [Did Biden Bet the Future of America on the "Lithium Triangle"?]() FREE investor's report details the plan to cut more ties with China and how it could create the next boom for early investors. But you must act fast. [Discover the one company set to break China's grip on lithium.]() = --------------------------------------------------------------- And there you have it--7 Five Day Gainers of all US Exchanges. Sincerely, The Editor, MarketSectorDaily.com [Unsubscribe](=) Sandpiper Marketing Group, LLC PO Box 407 Mt. Mourne, North Carolina 28123 United States (845) 803-0954 If you no longer wish to receive our emails, click the link below: [Unsubscribe]( MarketSectorDaily.com part of Sandpiper Marketing Group, LLC 165 Lockerbie Lane Mooresville, North Carolina 28115 United States (877) 411-9808

Marketing emails from marketsectordaily.com

View More
Sent On

09/05/2024

Sent On

09/05/2024

Sent On

09/05/2024

Sent On

09/05/2024

Sent On

08/05/2024

Sent On

08/05/2024

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2025 SimilarMail.